OriGene Technologies has acquired Blue Heron Biotechnology from its venture investment backers, including Nasdaq-listed Invitrogen.
OriGene Technologies, a US-based serial acquirer of gene development companies, has acquired Blue Heron Biotechnology from its venture investment backers, including Nasdaq-listed Invitrogen.
News provider VentureWire said Blue Heron was OriGene’s fourth acquisition after it raised $16m in its series B round in March from venture investors IDG-Accel, a joint venture between publisher International Data Group and venture capital firm Accel, SBI & TH Venture Capital Enterprise, a jointly funded entity by the Tsinghua holding group and Japan-based VC firm…
